Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma-Reference-Cited by-同舟云学术

Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma

Published:2005-10 Issue:1 Volume:131 Page:71-73
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Zangari Maurizio,Esseltine Dixie,Lee Choon-Kee,Barlogie Bart,Elice Francesca,Burns Michael J.,Kang Seung-Hee,Yaccoby Shmuel,Najarian Kevin,Richardson Paul,Sonneveld Peter,Tricot Guido

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2005.05733.x/fullpdf

Reference10 articles.

1. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma.

2. CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH-DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

3. Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma

4. Interleukin-6 prevents dexamethasone-induced myeloma cell death

Cited by 162 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. OROSOMUCOID PROTEIN 1 regulation of sphingolipid synthesis is required for nodulation in Aeschynomene evenia;Plant Physiology;2023-12-01

2. Significance of alkaline Phosphatase After Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2023-12

3. Prevalence and clinical outcomes of vitamin D deficiency among Japanese multiple myeloma patients: a single-center observational study;Supportive Care in Cancer;2023-09

4. Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors;International Journal of Hematology;2023-04-11

5. Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents;Journal of Bone and Mineral Metabolism;2023-03-01